Crossmark

Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%

Crossref DOI link: https://doi.org/10.1007/s00262-022-03359-2

Published Online: 2023-01-24

Published Print: 2023-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pons-Tostivint, E.

Hulo, P.

Guardiolle, V.

Bodot, L.

Rabeau, A.

Porte, M.

Hiret, S.

Demontrond, P.

Curcio, H.

Boudoussier, A.

Veillon, R.

Mayenga, M.

Dumenil, C.

Chatellier, T.

Gourraud, P. A.

Mazieres, J.

Bennouna, J.
License Information

Text and Data Mining valid from 2023-01-24

Version of Record valid from 2023-01-24
More Information

Article History

Received: 11 August 2022

Accepted: 23 December 2022

First Online: 24 January 2023

Change Date: 27 February 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s00262-023-03405-7

Declarations

:

: Pr BENNOUNA reports advisory board: AstraZeneca, Bristol-Myers Squibb, MSD, Jansen; Research: Amgen, AstraZeneca, Medimmune, Bayer, Boehringer Ingelheim, F. Hoffmann–La Roche Ltd, Innate Pharma, Merck, MSD, Novartis, Sanofi-Aventis, Daiichi; Honorarium: AstraZeneca, Bayer, Bristol Myers Squibb, MSD, Novartis, Daiichi, Jansen. Pr MAZIERES reports personal fees from Roche, Astra Zeneca, Pierre Fabre, Takeda, BMS, MSD, Jiangsu Hengruii, Blueprint, Daiichi, Novartis, Amgen; and grants from Roche, Astra Zeneca, Pierre Fabre, BMS. Dr Pons-Tostivint reports advisory board from BMS, SANOFI, TAKEDA. Other authors have no relevant financial or non-financial interests to disclose.

Updates are available Correction dated 2023-02-27

Click to view Correction: https://doi.org/10.1007/s00262-023-03405-7